Euroscreen S.A.

Since its inception in 1994, Euroscreen has built a solid reputation for its target discovery programs and GPCR products (membranes, cell lines, Aequoscreen ^TM). Euroscreen now pursues a dual platform business model to provide these GPCR materials and capabilities to its drug discovery programs and its Euroscreen FAST business unit.

Our growing investments in drug discovery leverage :

• A high performance Drug Discovery platform validated by long term collaborations with pharma companies, including cutting edge high throughput functional screening platform and our small molecule chemical library

• Several promising internal drug discovery programs which represent the growing value for our company's future

• High value partnered programs with biotechnology and pharmaceutical companies

• 14 years of contact across the bio-pharma industry via products, services, licensing, publications and partnering has resulted in a strong reputation and name value

Euroscreen is using its current managerial, financial and scientific assets to develop a portfolio of internal drug candidate programs and identify new chemical entities (NCE) for out-licensing. These NCEs are being discovered through our internal R&D pipeline and also in partnerships with Cephalon and Alchemia, having complementary expertise to Euroscreen. The targets are derived from our existing patent portfolio as well as from other opportunities which are evaluated for competition, attraction for further licensing, innovation and feasibility with our discovery platform.

Euroscreen has also an affiliate, ChemCom SA dedicated to GPCRs involved in taste and olfaction.